Patient P-03027
Therapy response
Favorable
Tolerance
Favorable
GI state
Deteriorating
Inflammatory state
Deteriorating
Nutritional resilience
Declining
Discontinuation risk
34%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 ONX-7 started — Baseline state S20
What changed?
Trajectory is tracking the baseline prediction.
Primary contributors, last 14 days
- Inflammatory activity+16
- GI instability+10
- Nutritional resilience-5
- Toxicity+4
What helped?
No interventions yet.
LIFE OS recommendation
No intervention is indicated right now. The trajectory is stable relative to similar patients. See what worked for similar patients.
Daily trackers
Molecule settingsThe trackers this program marks as important, last 14 days vs the 14 before.
Energy level
Daily log5.4/10
stable · +0.2 vs previous 14 d
Stress level
Daily log4/10
improving · -0.4 vs previous 14 d
Pessimism score
Daily log3.4/10
improving · -0.2 vs previous 14 d
Sleep quality
Wearable51.7/100
improving · +2.4 vs previous 14 d
Libido
Daily log4.4/10
stable · +0.2 vs previous 14 d
HRV
Wearable48.3 ms
stable · +0.2 vs previous 14 d
Toxicity
Blood29.5/100
improving · -1.6 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →Heading towards failing · 64 from the failing basin, 23 from restoration.
Would help
- No untried action with strong evidence. Compose one from primitives.
- More proteinGI -3.9 next day on high-intake days · n 18
Would not help
- Keep histamine lowGI +5.6 next day on high-intake days · n 27
- Keep fat lowGI +3.9 next day on high-intake days · n 19
- Keep lactose lowGI +2.8 next day on high-intake days · n 17
State influencers · digestive
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Histamine load+5.6detractor · 95%
- Dietary fat load+3.9detractor · 95%
- Protein-3.9supporter · 95%
- Lactose+2.8detractor · 72%
- Caffeine+1no signal · 23%
- Alcohol+0.1no signal · 15%
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Mucosal barrier integrity ↓60
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Butyrate / short-chain fatty acid production ↓35
- MicrobiomeButyrate capacity 26/100
- Drug metabolism and exposure ↑35
- DNADPYD *2A → slower clearance
- Inflammatory signalling ↑20
- MicrobiomeBacteroides fragilis expansion
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- DPYD *2A heterozygousSlower drug clearance
- CYP2D6 Normal metabolizerExpected exposure
Microbiome
Shannon diversity 2.6 · butyrate capacity 26/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiNormal
- Bacteroides fragilisHigh
- Bifidobacterium longumNormal
- EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 52 ms
- Sleep
- 7.1 h
- Steps
- 7,249
- Resting HR
- 60 bpm
Daily log: GI score 26, nutritional resilience 56, adherence 92.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Keep meals regular; three to four moderate portions spaced through the day
- Include a cooked vegetable portion with each main meal
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Log the daily check-in; one line is enough
- Keep the current walking rhythm
- Keep the sleep window steady
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- No additional supplements this week
- Fictional demo item: continue vitamin D as before
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-03105 | 42% | S12 | AD-05 | no change | 60 |
| P-03204 | 37% | S16 | AD-05 | improved | 48 |
| P-03482 | 36% | S05 | AD-05 | no change | 67 |
| P-03187 | 35% | S12 | AD-05 | no change | 80 |
| P-03351 | 33% | S07 | AD-05 | no change | 51 |
| P-03111 | 32% | S07 | AD-05 | no change | 48 |
| P-03424 | 32% | S12 | AD-05 | improved | 41 |
| P-03208 | 34% | S02 | BR-03 | improved | 57 |
| P-03277 | 31% | S14 | BR-03 | improved | 41 |
| P-03308 | 30% | S04 | BR-03 | improved | 39 |
| P-03031 | 30% | S16 | CR-01 | improved | 49 |
| P-03375 | 38% | S09 | DT-01 | improved | 52 |